X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

TPST

Closed

Tempest Therapeutics Inc

1.24
-0.01 (-0.80%)
Last Update: 06 Sep 2024 23:04:00
Yesterday: 1.25
Day's Range: 1.23 - 1.31
Send
When Written:
 
3.47
Tempest Therapeutics Inc is a clinical-stage biotechnology company that is focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer and other diseases. The company's proprietary platform is based on the modulation of the tumor microenvironment, which plays a critical role in cancer progression and resistance to therapy.

Tempest's lead candidate, TPST-1120, is a small molecule inhibitor of the A2A adenosine receptor, which is overexpressed in various types of cancer and has been shown to promote tumor growth and immune suppression. TPST-1120 is currently being evaluated in multiple clinical trials for the treatment of solid tumors and hematologic malignancies.

Tempest also has a pipeline of preclinical programs targeting other key components of the tumor microenvironment, including myeloid-derived suppressor cells, regulatory T cells, and tumor-associated macrophages. The company is headquartered in South San Francisco, California, and was founded in 2016.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:3.149.235.158
X